We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

22 hedge funds and large institutions have $29.1M invested in Evofem Biosciences, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
22
Holders Change
+22
Holders Change %
–
% of All Funds
0.59%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
22
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CV
Clarus Ventures
Massachusetts
+$8.99M
2
TAM
Tiverton Asset Management
Delaware
+$7.13M
3
PSC
Piper Sandler & Co
Minnesota
+$3.69M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$2.31M
5
LOAMU
Lombard Odier Asset Management (USA)
New York
+$1.63M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CV
1
Clarus Ventures
Massachusetts
$8.01M +$8.99M +11,905 New
TAM
2
Tiverton Asset Management
Delaware
$6.36M +$7.13M +9,444 New
PSC
3
Piper Sandler & Co
Minnesota
$3.29M +$3.69M +4,879 New
Federated Hermes
4
Federated Hermes
Pennsylvania
$2.06M +$2.31M +3,060 New
LOAMU
5
Lombard Odier Asset Management (USA)
New York
$1.45M +$1.63M +2,155 New
DCM
6
DAFNA Capital Management
California
$1.4M +$1.56M +2,072 New
JC
7
JBF Capital
Colorado
$1.07M +$1.2M +1,590 New
UOC
8
UBS O'Connor
Illinois
$1.04M +$1.17M +1,551 New
FCM
9
Farallon Capital Management
California
$935K +$1.05M +1,389 New
NIP
10
Nicholas Investment Partners
California
$899K +$1.01M +1,336 New
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$712K +$798K +1,057 New
Ameriprise
12
Ameriprise
Minnesota
$477K +$536K +709 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$374K +$420K +556 New
Millennium Management
14
Millennium Management
New York
$278K +$311K +412 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$190K +$213K +282 New
Deutsche Bank
16
Deutsche Bank
Germany
$131K +$148K +196 New
Goldman Sachs
17
Goldman Sachs
New York
$128K +$144K +190 New
California Public Employees Retirement System
18
California Public Employees Retirement System
California
$122K +$149K +197 New
SIM
19
Spark Investment Management
New York
$114K +$128K +170 New
BPC
20
Banque Pictet & Cie
Switzerland
$82K +$91.4K +121 New
Morgan Stanley
21
Morgan Stanley
New York
$17K +$18.9K +25 New
BIM
22
BlackRock Investment Management
Delaware
$5K +$6.04K +8 New

EVFM Hedge Fund Activity: Q4 2014 in Review

22 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q4 2014, worth a combined $29.1M.

Buyers outnumbered sellers: 22 funds opened new EVFM positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Clarus Ventures, opening a new position worth an estimated $8.99M.

  • 22 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q4 2014, up from 0 in Q3 2014.
  • Funds reported $29.1M of Evofem Biosciences, Inc. Common Stock stock for Q4 2014.
  • 22 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q4 2014 and 0 closed out, a net change of +22 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q4 2014 was Clarus Ventures, an estimated $8.99M added.

Based on aggregated 13F filings for Q4 2014.